From the Guidelines
The US Preventive Services Task Force (USPSTF) recommends screening for skin cancer as an effective preventive care service to improve health outcomes nationwide. This recommendation is based on the evidence of both the benefits and harms of the service, as well as an assessment of the balance between the two 1. The USPSTF makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms to improve the health of people nationwide.
When considering preventive care services, it is essential to individualize decision-making to the specific patient or situation, taking into account factors beyond just the evidence 1. The USPSTF recognizes that clinical decisions involve more considerations than evidence alone and that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms.
Some key points to consider when implementing screening for skin cancer include:
- The USPSTF bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance 1
- Clinicians should understand the evidence but individualize decision-making to the specific patient or situation 1
- The USPSTF does not consider the costs of providing a service in this assessment, but rather focuses on the clinical benefits and harms 1
From the Research
Previs Studies
- There are no research papers directly related to "Previs" in the provided evidence.
- The studies provided cover various topics such as the use of alteplase for posterior circulation ischemic stroke 2, advance directives and their impact on medical decision-making 3, direct-to-consumer prescription drug advertising 4, definitions and prerequisites of direct and indirect approaches for estimating reference limits 5, and the immune response during sepsis 6.
- None of these studies mention "Previs" or provide relevant information to answer questions about it.